Loading…
Protagonist Therapeutics, Inc. is projected to rise to $126.77 by 2027, a +24% move from its current price of $102.21. PTGX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $100.06 | $102.24 | $104.47 | +0.03% |
| May 30 | $99.20 | $102.28 | $105.45 | +0.07% |
| May 31 | $98.56 | $102.31 | $106.21 | +0.10% |
| Jun 1 | $98.02 | $102.34 | $106.86 | +0.13% |
| Jun 2 | $97.55 | $102.38 | $107.44 | +0.16% |
| Jun 3 | $97.14 | $102.41 | $107.97 | +0.20% |
| Jun 4 | $96.76 | $102.44 | $108.46 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $96.76 | $102.44 | $108.46 | +0.23% |
| Week 2 | $94.71 | $102.68 | $111.31 | +0.46% |
| Week 3 | $93.22 | $102.91 | $113.60 | +0.68% |
| Week 4 | $92.02 | $103.14 | $115.62 | +0.91% |
| Week 5 | $90.99 | $103.38 | $117.45 | +1.14% |
| Week 6 | $90.09 | $103.61 | $119.16 | +1.37% |
| Week 7 | $89.29 | $103.85 | $120.78 | +1.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics, Inc. (PTGX) is a biotechnology company focused on peptide therapeutics. The stock is currently priced at $99.19 per share and has a market capitalization of $6.38B, ranking 1173 by market capitalization among listed entities.
The stock’s price now sits near the 30-day range midpoint, with the forecast implying potential upside over the coming years. The multi-year outlook shows substantial upside, with higher average prices projected in later years such as 2030, 2040, and 2050, signaling a bullish long-term trajectory.
A major floor 22.0% below — a decisive break under it would weaken the trend.
The nearest floor, 3.8% below — buyers have tended to step in here.
The nearest ceiling, 3.7% above — a clean break opens room to run.
A major ceiling 7.4% above — clearing it would confirm fresh momentum.
Key PTGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PTGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $100.85 | Buy | $100.98 | Buy |
| MA 10 | $101.50 | Buy | $101.01 | Buy |
| MA 20 | $100.76 | Buy | $101.10 | Buy |
| MA 50 | $101.51 | Buy | $99.56 | Buy |
| MA 100 | $93.72 | Buy | $94.71 | Buy |
| MA 200 | $83.74 | Buy | $84.81 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.13 | Neutral |
| Stoch RSI (14) | 56.70 | Neutral |
| CCI (20) | 53.40 | Neutral |
| Williams %R (14) | -46.52 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | 2.87 | Buy |
| Bollinger %B (20,2) | 0.67 | Neutral |
| Stochastic %K (14) | 53.48 | Neutral |
| TRIX (15) | 0.00 | Buy |
| Awesome (5,34) | -0.76 | Sell |
| Ultimate (7,14,28) | 49.17 | Neutral |
| Momentum (10) | 2.26 | Buy |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 100.40 | Buy |
| ADX (14) | 7.82 | Neutral |
| ATR (14) | 2.21 | Info |
The 30-day technical picture is described as BULLISH. The RSI(14) is 50, with the 50-day simple moving average at $101.25 and the 200-day simple moving average at $83.24. Nearby support is at $97.57 and resistance at $105.98, framing a 30-day range of $85.54 to $115.02.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $79.73 | $102.21 | $143.18 | 0% | Neutral | |
| $102.58 | $126.77 | $164.66 | +24% | Bullish | |
| $124.44 | $157.03 | $209.98 | +54% | Bullish | |
| $143.33 | $184.05 | $251.88 | +80% | Bullish | |
| $172.96 | $225.54 | $314.80 | +121% | Bullish | |
| $206.88 | $273.57 | $388.50 | +168% | Bullish | |
| $224.18 | $300.33 | $433.21 | +194% | Bullish | |
| $245.87 | $333.43 | $487.83 | +226% | Bullish | |
| $261.42 | $358.63 | $531.62 | +251% | Bullish | |
| $276.61 | $383.65 | $575.71 | +275% | Bullish | |
| $456.36 | $665.06 | $1,050.86 | +551% | Bullish | |
| $954.37 | $1,511.47 | $2,577.55 | +13.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $79.73 | $102.21 | $119.57 | +0.00% |
| June 2026 | $87.07 | $101.79 | $121.48 | -0.41% |
| July 2026 | $89.46 | $105.28 | $127.00 | +3.43% |
| August 2026 | $92.18 | $109.04 | $132.62 | +3.57% |
| September 2026 | $91.90 | $109.17 | $133.68 | +0.12% |
| October 2026 | $92.37 | $110.17 | $135.73 | +0.91% |
| November 2026 | $95.10 | $113.81 | $140.97 | +3.31% |
| December 2026 | $95.79 | $115.01 | $143.18 | +1.06% |
Click any year to see its month-by-month PTGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PTGX price prediction for 2026 points to an average of $102.21 (low $79.73, high $143.18) — a potential gain of 0% on today's $102.21. Price action looks broadly range-bound.
In 2027, PTGX is projected to trade between $102.58 and $164.66, averaging $126.77 — a potential gain of +24% from today's $102.21. That is up +24% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Protagonist Therapeutics, Inc.'s 2028 outlook centres on $157.03, within a $124.44 to $209.98 range. That is up +24% on the projected 2027 average. That marks a +54% change versus current levels. Momentum favours further upside here.
By 2029, PTGX could reach as high as $251.88, with a base case around $184.05 and support toward $143.33 — roughly +80% from $102.21. Buyers look set to stay in control over this stretch.
Expect PTGX to range from $172.96 to $314.80 through 2030. The $225.54 average target implies a +121% move from current prices. That is up +23% on the projected 2029 average. Momentum favours further upside here.
The PTGX price prediction for 2031 points to an average of $273.57 (low $206.88, high $388.50) — a potential gain of +168% on today's $102.21. Buyers look set to stay in control over this stretch.
In 2032, PTGX is projected to trade between $224.18 and $433.21, averaging $300.33 — a potential gain of +194% from today's $102.21. That is up +10% on the projected 2031 average. Momentum favours further upside here.
Protagonist Therapeutics, Inc.'s 2033 outlook centres on $333.43, within a $245.87 to $487.83 range. That is up +11% on the projected 2032 average. That marks a +226% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, PTGX could reach as high as $531.62, with a base case around $358.63 and support toward $261.42 — roughly +251% from $102.21. Momentum favours further upside here.
Expect PTGX to range from $276.61 to $575.71 through 2035. The $383.65 average target implies a +275% move from current prices. That is up +7% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The PTGX price prediction for 2040 points to an average of $665.06 (low $456.36, high $1,050.86) — a potential gain of +551% on today's $102.21. Momentum favours further upside here.
In 2050, PTGX is projected to trade between $954.37 and $2,577.55, averaging $1,511.47 — a potential gain of +13.8x from today's $102.21. That is up +127% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PTGX today (≈ 9.783778 PTGX) could be worth
$14,787.9
+$13,787.9 (+1379%) by 2050 · US Dollar
Based on the average projected PTGX price of $1,511.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PTGXwould be worth at today's price.
$1,000 invested in PTGX on May 27, 2025 (≈ 21.537799 PTGX) would be worth
$2,201.38
+$1,201.38 (+120.1%) today · 2.20× · US Dollar
Based on a PTGX entry price of $46.43 vs. today's $102.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $100.88 | $1,013.18 | +1.3% |
| 1 month ago | $98.51 | $1,037.56 | +3.8% |
| 3 months ago | $88.39 | $1,156.35 | +15.6% |
| 6 months ago | $90 | $1,135.67 | +13.6% |
| 1 year ago | $46.43 | $2,201.38 | +120.1% |
| All time (5.0y) ago | $34.14 | $2,993.85 | +199.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PTGX forecast.
Our base-case forecast reaches $200.00 around 2030.
Implied market cap at $200.00: $12.86B
The multi-year forecast shows a clearly rising path after 2026. The 2026 forecast has a min of $79.73, an avg of $99.19, and a max of $139.34 with a 0% ROI and NEUTRAL sentiment. From 2027 onward, the outlook turns BULLISH with higher averages and positive ROIs: 2027 avg $123.28 (ROI 24.3), 2028 avg $153.88 (ROI 55.1), 2029 avg $179.26 (ROI 80.7), 2030 avg $220.49 (ROI 122.3).
The growth continues through 2031–2035 with stronger upside, culminating in 2035 avg $374.12 (ROI 277.2). The forecast accelerates further into 2040 with avg $656.12 (ROI 561.5) and a max of $1,048.27, and by 2050 the avg is $1,486.04 (ROI 1,398.2) with a max of $2,567.92. These figures reflect a bullish outlook across the longer horizon, but they are estimates and carry uncertainty and no guarantee of future results.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $220.49, with a min of $168.11 and a max of $309.98. The forecast also indicates a 122.3% ROI and bullish sentiment.
The forecast turns bullish from 2027 onward, with rising average prices and positive ROIs (e.g., 2027 avg $123.28, ROI 24.3; 2030 avg $220.49, ROI 122.3; 2050 avg $1,486.04, ROI 1,398.2). The 2026 outlook is neutral, and these are estimates, not guarantees.
Yes. The 2030 max forecast is $309.98, and by 2031–2035 the max values rise above $300 (e.g., 2031 max $385.43, 2032 max $426.83, 2033 max $481.68, 2034 max $527.06, 2035 max $566.77). Future years show even higher max values.
The current price is $99.19 per share and the market capitalization is $6.38B. The company is ranked 1173.
The 30-day picture is described as BULLISH. RSI(14) is 50, SMA50 is $101.25, SMA200 is $83.24. The 30-day range spans $85.54 to $115.02, with support at $97.57 and resistance at $105.98.
Protagonist Therapeutics, Inc. Community Discussion
0Share your Protagonist Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.